Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / ADS
-
Total 13F shares
-
21,916,214
-
Share change
-
-2,904,115
-
Total reported value
-
$60,638,220
-
Put/Call ratio
-
200%
-
Price per share
-
$2.82
-
Number of holders
-
58
-
Value change
-
-$13,764,100
-
Number of buys
-
21
-
Number of sells
-
36
Institutional Holders of Silence Therapeutics plc - ADS (SLN) as of Q1 2025
As of 31 Mar 2025,
Silence Therapeutics plc - ADS (SLN) was held by
58 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
21,916,214 shares.
The largest 10 holders included
TCG Crossover Management, LLC, Siren, L.L.C., Redmile Group, LLC, MORGAN STANLEY, Lombard Odier Asset Management (USA) Corp, Frazier Life Sciences Management, L.P., Vivo Capital, LLC, Nantahala Capital Management, LLC, Nextech Invest, Ltd., and CANTOR FITZGERALD, L. P..
This page lists
58
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.